![](images/graphics/blank.gif)
Tyrosine kinases
-
Predicting short-term efficacy and intracranial progression-free survival (iPFS) in epidermal growth factor receptor gene mutated (EGFR-mutated) lung adenocarcinoma patients with brain metastases who receive third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy was of great significance for individualized treatment.
15p
vishanshan
27-06-2024
1
1
Download
-
Both first and second-generation EGFR-TKIs are recommended in advanced NSCLC with common EGFR mutations. However, there are few data on the difference in efficacy of EGFR-TKIs based on the type of EGFR mutation and agents.
10p
vishanshan
27-06-2024
1
1
Download
-
Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and c-Kit. This phase II study aimed to assess the efficacy and safety of anlotinib, either alone or in combination with bevacizumab (Bev) for recurrent high-grade glioma (rHGG) (NCT04822805, 30/03/2021).
11p
vishanshan
27-06-2024
2
1
Download
-
Despite advancements in managing metastatic clear cell renal carcinoma (mccRCC) through antiangiogenic tyrosine kinase inhibitors and immunotherapy, there remains a demand for novel treatments for patients experiencing progression despite the use of these medications.
8p
vishanshan
27-06-2024
2
1
Download
-
Combination therapy is the primary treatment for unresectable hepatocellular carcinoma (u-HCC). The hepatic functional reserve is also critical in the treatment of HCC. In this study, u-HCC was treated with combined hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and programmed cell death protein-1 (PD-1) inhibitors to analyze the therapeutic response, progression-free survival (PFS), and safety.
10p
vishanshan
27-06-2024
2
1
Download
-
Evaluation of human epidermal growth factor receptor 2 (HER2) overexpression caused by erbb2 receptor tyrosine kinase 2 (ERBB2) amplification (AMP) by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is essential for treating unresectable metastatic gastric cancer (GC).
13p
vikoch
27-06-2024
1
1
Download
-
In the era of targeted therapies, the influence of aging on cancer management varies from one patient to another. Assessing individual frailty using geriatric tools has its limitations, and is not appropriate for all patients especially the youngest one.
8p
vikoch
27-06-2024
1
1
Download
-
Lung cancer is a leading cause of cancer-related mortality worldwide, and effective therapies are limited. Lung cancer is a leading cause of cancer-related mortality worldwide with limited effective therapy. Sorafenib is a multi-tyrosine kinase inhibitor frequently used to treat numerous types of malignant tumors.
12p
vikoch
27-06-2024
1
1
Download
-
The superior efficacy of concurrent thoracic radiotherapy (TRT) and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been proven in locally advanced and advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations.
10p
vikoch
27-06-2024
1
1
Download
-
The irreversible epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) afatinib and dac‑ omitinib are approved for first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and dacomitinib in this setting.
11p
vikoch
27-06-2024
1
1
Download
-
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Acquired functional mutations in the tyrosine-protein kinase growth factor receptor proto-oncogene (KIT) and platelet-derived growth factor-alpha gene lead to increased tyrosine kinase activity, which is considered a key factor in the pathogenesis of GIST.
14p
vikoch
27-06-2024
1
1
Download
-
This research aimed to investigate the utility and predictive value of the CRAFITY score in HCC patients receiving combined of TACE plus ICIs and TKIs therapy. We performed a single center retrospective study to broaden the use of the CRAFITY score.
12p
vikoch
27-06-2024
2
1
Download
-
For brain metastases (BMs) from EGFR/ALK-positive non-small cell lung cancer (NSCLC), the best time to administer tyrosine kinase inhibitors (TKIs) and brain radiotherapy (RT) has not been identified. This analysis was an attempt to solve this problem in part.
9p
vikoch
27-06-2024
1
1
Download
-
Pazopanib hydrochlorid (biệt dược trên thị trường: Votrient) là một loại thuốc chống ung thư do hãng Novartis sản xuất. Nghiên cứu này được thực hiện với mục tiêu: nâng cấp được quy mô tổng hợp chất 3-methyl6-nitro-1H-indazol (3) đạt hiệu suất cao ở mức 180 g/mẻ với các điều kiện được cải tiến.
9p
visergeyne
18-06-2024
1
0
Download
-
The past decade has seen a significant increase of research aimed at discovering new drugs for treating cancer, and the increasing number of new antineoplastic drugs approved by regulatory agencies reflects this. Until now, details on the synthesis of these newer agents have been scattered in various journals and in US and European patents.
230p
vimeyers
29-05-2024
4
2
Download
-
Bài viết trình bày mô tả một số đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị imatinib ở bệnh nhân u mô đệm dạ dày ruột (GISTs). Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu trên 36 bệnh nhân u mô đệm dạ dày ruột điều trị bằng imatinib.
4p
vicarlos
21-05-2024
3
1
Download
-
Bài viết trình bày đánh giá đột biến gen ở những bệnh nhân ung thư phổi biểu mô tuyến được điều trị phẫu thuật tại Bệnh viện Phổi Trung ương. Đánh giá đột biến gen ở những bệnh nhân ung thư phổi biểu mô tuyến được điều trị phẫu thuật tại Bệnh viện Phổi Trung ương.
6p
viambani
21-05-2024
11
2
Download
-
Bài viết trình bày đánh giá tỷ lệ đáp ứng và thời gian sống thêm không bệnh tiến triển của bệnh nhân ung thư phổi biểu mô tuyến giai đoạn IV có đột biến gen EGFR tại Bệnh viện Phổi Trung ương giai đoạn 2019-2022; Đánh giá các tác dụng không mong muốn của thuốc.
9p
viambani
21-05-2024
2
1
Download
-
We aimed to identify the T790M mutation rate and clinical factors predicting the occurrence of acquired T790M mutations in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after first- and secondgeneration tyrosine kinase inhibitor (TKI) treatment.
9p
vicarlos
16-05-2024
1
0
Download
-
Ebook "Current advances in osteosarcoma" summarizes molecular and genetic characteristics, new therapeutic ideas, and biological characteristics that have been uncovered in the past 10 years. Osteosarcoma is an aggressive malignant neoplasm and it is also the most common histological form of bone cancer. It accounts for approximately 56% of new bone tumors, making it the most primary malignant bone tumor in children and adolescents.
358p
tracanhphuonghoa1007
22-04-2024
6
1
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)